AI assistant
Altimmune, Inc. — Director's Dealing 2025
Sep 29, 2025
33207_dirs_2025-09-29_5c74c9c3-134c-4ca5-a597-56e3130cef90.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2025-09-25
Reporting Person: GILL JOHN (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-06 | Common Stock, par value $0.0001 | G | 2714 | — | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-09-25 | Stock Options (option to buy) | $3.92 | A | 48800 | Acquired | 2035-09-25 | Common Stock, par value $0.0001 (48800) | Direct |
Footnotes
F1: Represents a bona fide gift of 2,714 shares of common stock made on January 6, 2022.
F2: Certain Section 16 reports previously filed by the reporting person inadvertently overstated the reporting person's direct common stock ownership by 57 shares. As of the date of this filing, the reporting person does not hold any shares of common stock directly or indirectly.
F3: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date.